Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Stopped early · Phase 1/Phase 2
Conditions studied: Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia, Pneumonia, Viral, Lung Diseases, Respiratory Tract Disease, Respiratory Tract Infections, Coronaviridae Infections, Nidovirales Infections, RNA Virus Infections, Virus Disease, Immunologic Disease, ARDS, Immunologic Factors, Physiological Effects of Drugs, Antiviral Agents, Anti-infective Agents, Analgesics, Antimetabolites, Antineoplastic
In brief
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.
Key facts
- Study ID
- NCT04365101
- Run by
- Celularity Incorporated
- People needed
- 7
- Starts
- 2020-09-02
- Expected to finish
- 2023-02-15
- Last updated by the study team
- 2026-06-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UC Irvine — Irvine, California, United States
- Atlantic Health — Morristown, New Jersey, United States
- Atlantic Health — Summit, New Jersey, United States
- Multicare Health System — Tacoma, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.